Isolated Distal Deep Vein Thrombosis in the Direct Oral Anticoagulant (DOAC) Era – Should Our Management Change?
Table 1.
Outline of baseline demographics of DOAC and Warfarin era cohorts
| |
Total Population (n=247) |
DOAC Era (n=103) |
Warfarin Era (n=144) |
p-value |
| Male gender |
50.6% (n=125) |
47.6% (n=49) |
52.8% (n=76) |
0.42 |
| Median age years (range) |
56 (22-95) |
53 (22-85) |
62 (25-95) |
0.06 |
| Past history of VTE |
18.2% (n=45) |
18.4% (n=19) |
18.1% (n=26) |
0.94 |
| Provoked events |
57.9 (n=143) |
45.6% (n=47) |
66.7% (n=96) |
<0.01 |
| Anticoagulant prescribed: |
|
|
|
|
| Rivaroxaban |
|
94.2% |
|
|
| Apixaban |
|
5.8% (n=6) |
|
|
| Warfarin |
|
|
91.0% (n=131) |
|
| Enoxaparin |
|
|
9.0% (n=13) |
|
| Limited treatment duration (months): |
|
|
|
|
| Provoked |
3 (<1-12) |
3 (<1-9) |
3 (<1-12) |
|
| Unprovoked |
3 (<1-12) |
3 (<1-10) |
5 (1-12) |
<0.01 |
| Long term treatment: |
|
|
|
|
| Provoked |
5.6% (n=8) |
0% (n=0) |
8.3% (n=8) |
0.04 |
| Unprovoked |
11.5% (n=12) |
(n=2) |
20.8% (n=10) |
<0.01 |
| Median follow-up months (range) |
27 (2-70) |
53 (20-70) |
22 (2-31) |
<0.01 |
|
|
